Patent · US Active

Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof

US11186648B2 · kind B2 · utility

1Cited by

2References

11Claims

0Family size

Assignees

LYVGEN BIOPHARMA HOLDINGS LIMITED · CN
LYVGEN BIOPHARMA (SUZHOU) CO., LTD. · CN

Inventors

Jieyi Wang · Lake Bluff, US
Yi-Ting Wu · Shanghai, CN

Key dates

Filing date	Mar 19, 2021
Grant date	Nov 30, 2021
Priority date	—
Expiry date	Mar 19, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure provides CD40-binding molecules comprising engineered human IgG domains, for example, human IgG1, IgG2, and IgG4 variants having mutations in the hinge domain, which exhibit altered binding activity to one or more Fcγ receptors. Also described herein are methods for selectively activating or inhibiting immune responses in a subject using the CD40-binding molecules.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.